{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:49:07Z","timestamp":1788349747948,"version":"build-2803163510"},"reference-count":75,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EU fund MSCA-ETN","award":["860325"],"award-info":[{"award-number":["860325"]}]},{"name":"Italian Ministry PRIN grant","award":["2017E44A9P"],"award-info":[{"award-number":["2017E44A9P"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that sits in the top 10 leading causes of death in the world today and is the current leading cause of death among infectious diseases. Although there is a licensed vaccine against TB, the Mycobacterium bovis bacilli Calmette\u2013Gu\u00e9rin (BCG) vaccine, it has several limitations, namely its high variability of efficacy in the population and low protection against pulmonary tuberculosis. New vaccines for TB are needed. The World Health Organization (WHO) considers the development and implementation of new TB vaccines to be a priority. Subunit vaccines are promising candidates since they can overcome safety concerns and optimize antigen targeting. Nevertheless, these vaccines need adjuvants in their formulation in order to increase immunogenicity, decrease the needed antigen dose, ensure a targeted delivery and optimize the antigens delivery and interaction with the immune cells. This review aims to focus on adjuvants being used in new formulations of TB vaccines, namely candidates already in clinical trials and others in preclinical development. Although no correlates of protection are defined, most research lines in the field of TB vaccination focus on T-helper 1 (Th1) type of response, namely polyfunctional CD4+ cells expressing simultaneously IFN-\u03b3, TNF-\u03b1, and IL-2 cytokines, and also Th17 responses. Accordingly, most of the adjuvants reviewed here are able to promote such responses. In the future, it might be advantageous to consider a wider array of immune parameters to better understand the role of adjuvants in TB immunity and establish correlates of protection.<\/jats:p>","DOI":"10.3390\/cells10010078","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T10:35:12Z","timestamp":1609842912000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5574-0116","authenticated-orcid":false,"given":"Ana Rita","family":"Franco","sequence":"first","affiliation":[{"name":"Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-8224","authenticated-orcid":false,"given":"Francesco","family":"Peri","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.4110\/in.2018.18.e17","article-title":"Development of New Preventive and Therapeutic Vaccines for Tuberculosis","volume":"18","author":"Kwon","year":"2018","journal-title":"Immune Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"ref_3","unstructured":"(2020, November 03). World Health Organization Global Tuberculosis Report. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240013131."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00100-19","DOI":"10.1128\/CMR.00100-19","article-title":"Tuberculosis Vaccine Development: Progress in Clinical Evaluation","volume":"33","author":"Sable","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104289","DOI":"10.1016\/j.phrs.2019.104289","article-title":"Non-antibiotic adjunctive therapy: A promising approach to fight tuberculosis","volume":"146","author":"Khameneh","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_6","first-page":"263","article-title":"Novel approaches to tuberculosis vaccine development","volume":"56","author":"Kaufmann","year":"2017","journal-title":"Int. J. Infect. Dis. Ijid Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.14235","article-title":"Vaccine innovations for emerging infectious diseases\u2014a symposium report","volume":"1462","author":"Cable","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Stewart, E., Triccas, J.A., and Petrovsky, N. (2019). Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms, 7.","DOI":"10.3390\/microorganisms7080255"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Martin, C., Aguilo, N., Marinova, D., and Gonzalo-Asensio, J. (2020). Update on TB Vaccine Pipeline. Appl. Sci., 10.","DOI":"10.3390\/app10072632"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s12272-017-0969-z","article-title":"Vaccine adjuvants: Smart components to boost the immune system","volume":"40","author":"Bastola","year":"2017","journal-title":"Arch. Pharm. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ilar\/ily018","article-title":"Rational Design and in vivo Characterization of Vaccine Adjuvants","volume":"59","author":"Schmidt","year":"2018","journal-title":"Ilar J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/14760584.2019.1604231","article-title":"Selection of adjuvants for vaccines targeting specific pathogens","volume":"18","author":"Sarkar","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development: From classic to clinical candidates","volume":"39","author":"Li","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nm.4465","article-title":"The role of vaccines in preventing bacterial antimicrobial resistance","volume":"24","author":"Jansen","year":"2018","journal-title":"Nat. Med."},{"key":"ref_15","unstructured":"(2020, November 03). World Health Organization WHO Preferred Product Characteristics for New Tuberculosis Vaccines. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/273089."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis","volume":"18","author":"Schrager","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117594","DOI":"10.1016\/j.lfs.2020.117594","article-title":"Tuberculosis vaccine: A journey from BCG to present","volume":"252","author":"Fatima","year":"2020","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S2213-2600(19)30274-7","article-title":"Insights and challenges in tuberculosis vaccine development","volume":"7","author":"McShane","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2017.01262","article-title":"Polyfunctional CD4(+) T Cells As Targets for Tuberculosis Vaccination","volume":"8","author":"Lewinsohn","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-065X.2008.00702.x","article-title":"The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis","volume":"226","author":"Cooper","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","article-title":"Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis","volume":"21","author":"Moguche","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chikh, G., Luu, R., Patel, S., Davis, H.L., and Weeratna, R.D. (2016). Effects of KLK Peptide on Adjuvanticity of Different ODN Sequences. Vaccines, 4.","DOI":"10.3390\/vaccines4020014"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/20477724.2017.1351080","article-title":"New findings of Toll-like receptors involved in Mycobacterium tuberculosis infection","volume":"111","author":"Faridgohar","year":"2017","journal-title":"Pathog. Glob. Health"},{"key":"ref_25","first-page":"101949","article-title":"Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model","volume":"123","author":"Troy","year":"2020","journal-title":"A role for type I interferon. Tuberculosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpba.2018.05.048","article-title":"Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation","volume":"157","author":"Deshmukh","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bekker, L.-G., Dintwe, O., Fiore-Gartland, A., Middelkoop, K., Hutter, J., Williams, A., Randhawa, A.K., Ruhwald, M., Kromann, I., and Andersen, P.L. (2020). A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine, 21.","DOI":"10.1016\/j.eclinm.2020.100313"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","article-title":"Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial","volume":"199","author":"Suliman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.smim.2018.10.004","article-title":"Correlates of GLA family adjuvants\u2019 activities","volume":"39","author":"Reed","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dubois Cauwelaert, N., Desbien, A.L., Hudson, T.E., Pine, S.O., Reed, S.G., Coler, R.N., and Orr, M.T. (2016). The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146372"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CVI.00458-15","article-title":"Protection and Long-Lived Immunity Induced by the ID93\/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate","volume":"23","author":"Baldwin","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.vaccine.2016.03.029","article-title":"Pulmonary immunity and durable protection induced by the ID93\/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K","volume":"34","author":"Cha","year":"2016","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: First-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Larsen, S.E., Baldwin, S.L., Orr, M.T., Reese, V.A., Pecor, T., Granger, B., Dubois Cauwelaert, N., Podell, B.K., and Coler, R.N. (2018). Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines, 6.","DOI":"10.3390\/vaccines6020030"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93\u2008+\u2008GLA-SE in BCG-vaccinated healthy adults in South Africa: A randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Tameris","year":"2018","journal-title":"Lancet. Respir. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1038\/s41598-019-52146-0","article-title":"Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model","volume":"9","author":"Kwon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Rappuoli","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: Helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.3389\/fimmu.2019.02089","article-title":"Immunogenicity and Safety of the M72\/AS01(E) Candidate Vaccine Against Tuberculosis: A Meta-Analysis","volume":"10","author":"Ji","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3389\/fimmu.2020.01806","article-title":"The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72\/AS01(E) and MVA85A","volume":"11","author":"Ullah","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"379","author":"Hatherill","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2459","DOI":"10.1097\/MD.0000000000002459","article-title":"A Randomized, Controlled Safety, and Immunogenicity Trial of the M72\/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.smim.2018.10.003","article-title":"Immunocorrelates of CAF family adjuvants","volume":"39","author":"Pedersen","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.3389\/fimmu.2018.02825","article-title":"Dual-Isotope SPECT\/CT Imaging of the Tuberculosis Subunit Vaccine H56\/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization","volume":"9","author":"Thakur","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41385-019-0145-5","article-title":"Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection","volume":"12","author":"Woodworth","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/mi.2016.70","article-title":"Subunit vaccine H56\/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung","volume":"10","author":"Woodworth","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.vaccine.2018.04.055","article-title":"Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56\/CAF01 formulated as a spray-dried powder","volume":"36","author":"Thakur","year":"2018","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Roces, C.B., Hussain, M.T., Schmidt, S.T., Christensen, D., and Perrie, Y. (2019). Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting. Vaccines, 8.","DOI":"10.3390\/vaccines8010010"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A Functional Role for Antibodies in Tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3389\/fimmu.2018.01248","article-title":"Transcriptomics of the Vaccine Immune Response: Priming with Adjuvant Modulates Recall Innate Responses After Boosting","volume":"9","author":"Santoro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.carbpol.2017.02.030","article-title":"Potential of glucans as vaccine adjuvants: A review of the \u03b1-glucans case","volume":"165","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1016\/j.vaccine.2017.08.012","article-title":"Raw starch microparticles have immunostimulant activity in mice vaccinated with BCG and challenged with Mycobacterium tuberculosis","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.intimp.2004.07.024","article-title":"Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia","volume":"4","author":"Rodriguez","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.intimp.2006.07.028","article-title":"Mechanism of macrophage activation by (1,4)-\u03b1-d-glucan isolated from Tinospora cordifolia","volume":"6","author":"Nair","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dedloff, M.R., Effler, C.S., Holban, A.M., and Gestal, M.C. (2019). Use of Biopolymers in Mucosally-Administered Vaccinations for Respiratory Disease. Materials, 12.","DOI":"10.3390\/ma12152445"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1016\/j.vaccine.2019.04.027","article-title":"Raw starch microparticles as BCG adjuvant: Their efficacy depends on the virulence of the infection strains","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1021\/acs.molpharmaceut.6b00138","article-title":"Conjugation with an Inulin\u2013Chitosan Adjuvant Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein","volume":"13","author":"Yu","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.micpath.2018.05.035","article-title":"Are chitosan natural polymers suitable as adjuvant\/delivery system for anti-tuberculosis vaccines?","volume":"121","author":"Khademi","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Poecheim, J., Barnier-Quer, C., Collin, N., and Borchard, G. (2016). Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses. Vaccines, 4.","DOI":"10.3390\/vaccines4030032"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/21691401.2016.1146735","article-title":"Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen","volume":"45","author":"Amini","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1016\/j.vaccine.2018.07.040","article-title":"Polysaccharides as vaccine adjuvants","volume":"36","author":"Sun","year":"2018","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hellfritzsch, M., and Scherlie\u00df, R. (2019). Mucosal Vaccination via the Respiratory Tract. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080375"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.celrep.2018.04.003","article-title":"STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection","volume":"23","author":"Sogi","year":"2018","journal-title":"Cell Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","article-title":"Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection","volume":"7","author":"Counoupas","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1080\/21645515.2017.1368598","article-title":"Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection","volume":"13","author":"Trentini","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/trstmh\/tru206","article-title":"Aerosol immunisation for TB: Matching route of vaccination to route of infection","volume":"109","author":"McShane","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.vaccine.2017.07.073","article-title":"A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice","volume":"35","author":"Ahmed","year":"2017","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fimmu.2017.00585","article-title":"A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2(+) T Cells","volume":"8","author":"Yu","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:07:13Z","timestamp":1760159233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cells10010078"],"URL":"https:\/\/doi.org\/10.3390\/cells10010078","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}